AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8872649
Drug: CHO‐E (5.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO‐E (5.5% CHO‐electrolyte solution)
Trial: 6134039
Drug: Ceftriaxone (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (twice-daily as single-drug therapy)
Trial: 3932361
Drug: Polyvalent Pseudomonas
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyvalent Pseudomonas vaccine (three or four dose schedule)
Trial: 3932361
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (two dose schedule)
Trial: 20413518
Drug: Macroalbuminuria (AER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macroalbuminuria (AER >300 mg/24 h)
Trial: 20413518
Drug: Microalbuminuria (AER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microalbuminuria (AER 30-300 mg/24 h)
Trial: 20413518
Drug: AER <30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AER <30 mg/24 h
Trial: 20413518
Drug: Overall population
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall population with sustained eGFR <60 ml/min/1.73 m(2)
Trial: 11003631
Drug: Interferon alfa2a
RxNorm normalized name: ribavirin/peginterferon alfa2a 200 mg (1 tablet)-180 mcg MISCELL COMBINATION PACKAGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa2a plus amantadine (100 mg twice a day for 48 weeks)
Trial: 6146371
Drug: Brief counselling
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief counselling without anxiolytics
Trial: 27093778
Drug: Experimental oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental oral gel
Trial: 27093778
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available oral rinse
Trial: 27093778
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available mouth spray
Trial: 15685717
Drug: Drug A
RxNorm normalized name: Drug additive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug A
Trial: 15685717
Drug: Drug B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug B
Trial: 10593372
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg ganirelix
Trial: 10593372
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg ganirelix
Trial: 10593372
Drug: 0.50 mg
RxNorm normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg ganirelix
Trial: 9206242
Drug: Ganyan IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganyan IV and Western medicine
Trial: 1831630
Drug: Twice-daily oral
RxNorm normalized name: Ferriprox 1000 MG Twice-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily oral ondansetron treatment after a single i.v. dose prechemotherapy
Trial: 1831630
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times a day oral supplement regimen
Trial: 6984358
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid (200 mg) + Caffeine (100 mg)
Trial: 6984358
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid (200 mg) + Metoclopramide (10 mg)
Trial: 6984358
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid (200 mg) + Pyridoxine (300 mg)
Trial: 28396221
Drug: Voice therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice therapy (12-week protocol including vocal function exercise, hard attack, and resonance voice therapy)
Trial: 25468590
Drug: Epidural catheter
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural catheter insertion with 5 mL of isotonic sodium chloride solution containing epinephrine (1:200,000)
Trial: 25468590
Drug: Epidural catheter
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural catheter insertion with 5 mL of isotonic sodium chloride solution (control)
Trial: 21888678
Drug: Sequential mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential mixed mode (online followed by a paper questionnaire with reminder)
Trial: 9246253
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day for 3 months, then increased to 40 mg/day for non-responders at 6 months)
Trial: 9246253
Drug: Fluoxetine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (40 mg/day for non-responders at 6 months)
Trial: 8280820
Drug: Mineral oil
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral oil (2 to 8 tablespoons twice a day for two days)
Trial: 8280820
Drug: Pineapple-flavoured isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pineapple-flavoured isotonic intestinal lavage solution (20 ml/kg/h for 4 hours on two consecutive days)
Trial: 3329516
Drug: Traxanox sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traxanox sodium (120 mg)
Trial: 3329516
Drug: Traxanox sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traxanox sodium (360 mg)
Trial: 29064283
Drug: Clinician-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-guided treatment (n = 96)
Trial: 29064283
Drug: Self-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-guided treatment (n = 95)
Trial: 20728082
Drug: E2 (1
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2 (1 mg) plus drospirenone (2 mg)
Trial: 2151274
Drug: Zoladex, 3.6
RxNorm normalized name: Zoladex, 3.6 mg subcutaneous implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex, 3.6 mg depot, plus flutamide, 250 mg t.i.d.
Trial: 356792
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide aerosol, 800 microgram daily
Trial: 23241048
Drug: Pregabalin 300,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 300, 450 and 600 mg/day
Trial: 18184631
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg elemental zinc per day
Trial: 17015057
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (0.25 mg/kg)
Trial: 17015057
Drug: Low midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low midazolam clearance (<9.5 mL x kg(‐1) x min(‐1))
Trial: 11078841
Drug: Low-dose radiotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiotherapy (20 Gy of 6-MV photons to the macula of the affected eye)
Trial: 3371094
Drug: Oxygen delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen delivered by nasal prongs (3 L/min)
Trial: 3371094
Drug: Oxygen delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen delivered by economizer (3 L/min)
Trial: 30021626
Drug: Cocoa-based products
RxNorm normalized name: cocoa butter Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa-based products (mean intake 618.7 mg/day)
Trial: 30021626
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (mean intake 123.7 mg/day)
Trial: 26744107
Drug: Adjuvant interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant interferon alfa‐2b (IFN) therapy
Trial: 25515708
Drug: Long pulsed
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long pulsed 1064 nm Nd:YAG laser (LPND) treatment with three passes at a spot size of 12 mm, 20-24 J/cm² fluence, 12 ms width, and frequency of 2 Hz, for three sessions every four weeks
Trial: 20307245
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus adjuvant 5-fluorouracil (5-FU)-based chemotherapy
Trial: 18250501
Drug: Enteral rhEPO
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral rhEPO 400 U/kg, three times/week, plus FeSO4 3-6 mg/Kg/day (Study group)
Trial: 16368469
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone Therapy (HT) - 1mg estradiol + 0.5 mg norethisterone acetate
Trial: 12797703
Drug: Aminophylline 7.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline 7.35 mg/kg/day intravenously combined with anti-tuberculosis agents (isoniazid, rifampicin, ethambutol, pyrazinamide)
Trial: 11156459
Drug: Rectal compliance
RxNorm normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rectal compliance measurement using a latex rectal balloon filled with water at a rate of 60 ml per minute.
Trial: 7930085
Drug: Pre-admission programme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-admission programme for psychological preparation (videotape, tour, hospital play)
Trial: 3294976
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol (2 puffs)
Trial: 3294976
Drug: Inhaled metaproterenol
RxNorm normalized name: metaproterenol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled metaproterenol (2 puffs)
Trial: 3294976
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol (1 puff)
Trial: 3294976
Drug: Inhaled metaproterenol
RxNorm normalized name: metaproterenol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled metaproterenol (1 puff)
Trial: 29519283
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (lateral position ventilation + vibration sputum drainage)
Trial: 27614450
Drug: Tangyiping Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tangyiping Granules (TYP) 10 g twice daily for 12 weeks
Trial: 25360512
Drug: Lemon balm
RxNorm normalized name: LEMON BALM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemon balm preparation in a beverage
Trial: 25360512
Drug: Lemon balm
RxNorm normalized name: LEMON BALM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemon balm preparation in yoghurt
Trial: 23220316
Drug: Group 4:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 4: capsules pre-warmed and photocuring delayed for 2.4 minutes
Trial: 18484971
Drug: Ezetimibe 40
RxNorm normalized name: EZETIMIBE 40MG/SIMVASTATIN 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 40 mg/day
Trial: 12859261
Drug: Timolol maleate/dorzolamide
RxNorm normalized name: timolol maleate/dorzolamide HCl/bimatoprost/PF 0.5 %-2 %-0.01 % OPHTHALMIC DROPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol maleate/dorzolamide fixed combination (TDFC)
Trial: 12859261
Drug: Timolol maleate/pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol maleate/pilocarpine fixed combination (TPFC)
Trial: 8971300
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily, amoxycillin 1000 mg b.d., clarithromycin 250 mg b.d. for 7 days (LAC group)
Trial: 8971300
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily, amoxycillin 1000 mg b.d. for 7 days, plus azithromycin 500 mg once daily for 3 days (LAA group)
Trial: 6441544
Drug: Nicardipine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (mean dose: 69.4 mg per day, given three times a day)
Trial: 31612844
Drug: 0.8 Ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 Ratio of End-Expired Agent Concentration to Inspired Agent Concentration (group R)
Trial: 27577516
Drug: Split-bolus spectral
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-bolus spectral MDCT with virtual unenhanced imaging (1.5 mL/kg body weight, 4 mL/s flow rate)
Trial: 27577516
Drug: Conventional tri-phasic
RxNorm normalized name: Nu Skin Tri-Phasic White System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tri-phasic enhanced CT (1.5 mL/kg body weight, 4 mL/s flow rate)
Trial: 2576200
Drug: Mepindolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepindolol (20 mg/9.8 cm2 patch)
Trial: 2576200
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg/9.8 cm2 patch)
Trial: 23483
Drug: oral allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral allopurinol
Trial: 23483
Drug: sublingual procaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual procaine adenylate
Trial: 28808905
Drug: 801-mg tablet
RxNorm normalized name: pirfenidone 801 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 801-mg tablet (fasted state)
Trial: 28808905
Drug: 801-mg tablet
RxNorm normalized name: pirfenidone 801 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 801-mg tablet (fed state)
Trial: 28808905
Drug: Capsules (fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules (fasted state)
Trial: 28808905
Drug: Capsules (fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules (fed state)
Trial: 16330517
Drug: Post-treatment follow-up
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment follow-up and investigation
Trial: 11252695
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (4 capsules/day, each containing 250 mg of L‐ascorbic acid, 100 IU of dl‐a‐tocopherol acetate, and 150 mg of alpha‐lipoic acid)
Trial: 8272392
Drug: Simple out‐patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple out‐patient treatment
Trial: 30499426
Drug: Daily broccoli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily broccoli consumption (200 g cooked broccoli and 20 g raw daikon radish for 15 days, 100 g broccoli and 10 g daikon radish on day 16)
Trial: 16364933
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination of the digestive tract (SDD) oral gel
Trial: 8813907
Drug: Indapamide (IND)
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide (IND) 2.5 mg daily
Trial: 8813907
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 50 mg daily
Trial: 8813907
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 12.5 mg and 25 mg daily
Trial: 14621725
Drug: ganciclovir, 5
RxNorm normalized name: Ganciclovir, 500 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ganciclovir, 5 mg/kg twice daily (n = 12)
Trial: 14621725
Drug: no treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment (n = 11)
Trial: 4019541
Drug: Cefazolin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (25 mg/kg IV)
Trial: 4019541
Drug: Cefamandole (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (25 mg/kg IV)
Trial: 4019541
Drug: Cefoxitin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (25 mg/kg IV)
Trial: 29933528
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with CZBG (4 g, twice daily)
Trial: 12386036
Drug: Oral pristinamycin
RxNorm normalized name: pristinamycin
DrugBank: Pristinamycin (DB13704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pristinamycin
Trial: 12386036
Drug: Intravenous then
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous then oral penicillin
Trial: 7589027
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg) in sauna sessions
Trial: 7589027
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 mg) in sauna sessions
Trial: 7589027
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 mg) in control sessions
Trial: 7589027
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg) in control sessions
Trial: 2124433
Drug: surgery +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: surgery + MMC + 5‐FU (chemotherapy)
Trial: 7314008
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg aminophylline
Trial: 7314008
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg aminophylline
Trial: 30846366
Drug: Exogenously administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenously administered oxytocin (single dose)
Trial: 17893574
Drug: Oral gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral gabapentin 800 mg
Trial: 11474662
Drug: Alefacept 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept 0.025 mg/kg
Trial: 11474662
Drug: Alefacept 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept 0.075 mg/kg
Trial: 11474662
Drug: Alefacept 0.150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept 0.150 mg/kg
Trial: 2837830
Drug: Adjuvant CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant CAP chemotherapy
Trial: 2837830
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone or in combination with radiation therapy
Trial: 2837830
Drug: Preoperative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative therapy (chemotherapy alone or combination with radiation) followed by adjuvant chemotherapy
Trial: 2837830
Drug: Therapy directed
RxNorm normalized name: Chimeric Antigen Receptor immunotherapy directed against CLL-1 and CD33
DrugBank: CLL1-CD33 compound chimeric antigen receptor T cells (DB18568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy directed at CNS disease
Trial: 21707327
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel vs Placebo gel
Trial: 16443774
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin (0.3 mU . kg(‐1) . min(‐1)) in HNF-1beta mutation carriers
Trial: 16443774
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin (0.3 mU . kg(‐1) . min(‐1)) in HNF-1alpha mutation carriers
Trial: 16443774
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin (0.3 mU . kg(‐1) . min(‐1)) in control subjects
Trial: 16443774
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin (1.5 mU . kg(‐1) . min(‐1)) in all groups
Trial: 11467238
Drug: Combined regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined regimen of acetazolamide and dexamethasone (twice daily for 5 days)
Trial: 26147369
Drug: Virosomal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virosomal vaccine H5N1 (NIBRG‐14) with Matrix M adjuvant (1.5, 7.5 or 30 μg HA)
Trial: 26147369
Drug: Virosomal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virosomal vaccine H5N1 (NIBRG‐14) without Matrix M adjuvant (30 μg HA)
Trial: 26147369
Drug: Vaccine (with
RxNorm normalized name: Pneumococcal Polyvalent-23 Vaccine (with isolate 12)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (with or without Matrix M)
Trial: 18469018
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg rosiglitazone once daily (n=20)
Trial: 12565082
Drug: nisoldipine-ER (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nisoldipine-ER (20 to 40 mg)
Trial: 12565082
Drug: amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine (5 to 10 mg)
Trial: 7698380
Drug: Oxytocin dose
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin dose increments at 20-min intervals
Trial: 7698380
Drug: Oxytocin dose
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin dose increments at 60-min intervals